Literature DB >> 21850541

Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients.

Mahdieh Salimi1, Hossein Mozdarani, Keivan Majidzadeh.   

Abstract

ATM protein kinase plays a critical role in maintaining genome integrity by activating a biochemical chain reaction that in turn leads to cell cycle checkpoint activation and repair of DNA damage. Cyclin D1 acts in regulating the G1 phase of the cell cycle. Experimental and clinical studies suggest them to be involved in transformation and tumour progression. To elucidate the role of ATM and cyclin D1 expression in sporadic breast cancer, we investigated the possible link between their RNA expression levels in ductal carcinoma and normal adjacent versus normal breast tissues measured by Taqman real-time PCR in 119 breast tissues. Results showed that cyclin D1 over-expressed in 51.4% of breast tumours, whereas ATM expression was down regulated in 55% of breast tumours compared to both normal adjacent and normal controls (P ≤ 0.01). Cyclin D1 expression in adjacent normal and normal tissues was not significantly differed, whereas ATM expression in normal adjacent was lower than normal control (P ≤ 0.01). Over-expression of cyclin D1 correlated with ER(+) and/or PR(+) (oestrogen/progesterone receptor) status, whereas it mostly under-expressed in HER2(+) (human epidermal growth factor 2) tumours. ATM under-expression was more observed in triple-negative tumours (ER(-), PR(-) and HER2(-)). Our results indicated that reduced expression of the ATM and aberrant cyclin D1 expressions may contribute to the development and/or malignant progression of breast carcinomas also the latter could be involved in the regulation of hormone sensitivity associated with ER and PR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21850541     DOI: 10.1007/s12032-011-0043-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  56 in total

1.  Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.

Authors:  Mark W Landis; Basil S Pawlyk; Tiansen Li; Piotr Sicinski; Philip W Hinds
Journal:  Cancer Cell       Date:  2006-01       Impact factor: 31.743

Review 2.  Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression.

Authors:  Y Hosokawa; A Arnold
Journal:  Genes Chromosomes Cancer       Date:  1998-05       Impact factor: 5.006

3.  Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.

Authors:  Y Takano; H Takenaka; Y Kato; M Masuda; T Mikami; M Saegusa; I Okayasu
Journal:  J Cancer Res Clin Oncol       Date:  1999 Aug-Sep       Impact factor: 4.553

4.  Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer.

Authors:  Maria Giselle Peters; Maria del Carmen C Vidal; Liliana Giménez; Laura Mauro; Eduardo Armanasco; Carlos Cresta; Elisa Bal de Kier Joffé; Lydia Puricelli
Journal:  Oncol Rep       Date:  2004-11       Impact factor: 3.906

5.  The ATM gene is a target for epigenetic silencing in locally advanced breast cancer.

Authors:  Quynh N Vo; Wan-Ju Kim; Luke Cvitanovic; Donald A Boudreau; David G Ginzinger; Kevin D Brown
Journal:  Oncogene       Date:  2004-12-16       Impact factor: 9.867

6.  Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas.

Authors:  S Angèle; I Treilleux; A Brémond; P Tanière; J Hall
Journal:  Histopathology       Date:  2003-10       Impact factor: 5.087

7.  Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.

Authors:  E M Berns; J A Foekens; I L van Staveren; W L van Putten; H Y de Koning; H Portengen; J G Klijn
Journal:  Gene       Date:  1995-06-14       Impact factor: 3.688

8.  Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors.

Authors:  F Courjal; G Louason; P Speiser; D Katsaros; R Zeillinger; C Theillet
Journal:  Int J Cancer       Date:  1996-08-22       Impact factor: 7.396

9.  Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens.

Authors:  N R Wilcken; O W Prall; E A Musgrove; R L Sutherland
Journal:  Clin Cancer Res       Date:  1997-06       Impact factor: 12.531

10.  Breast conserving surgery versus mastectomy: cancer practice by general surgeons in Iran.

Authors:  Massoome Najafi; Mandana Ebrahimi; Ahmad Kaviani; Esmat Hashemi; Ali Montazeri
Journal:  BMC Cancer       Date:  2005-04-05       Impact factor: 4.430

View more
  10 in total

1.  Dysregulated expression of Dicer in invasive ductal breast carcinoma.

Authors:  Ali Akbar Poursadegh Zonouzi; Azim Nejatizadeh; Mohammad Rahmati-Yamchi; Hedieh Fardmanesh; Samira Shakerizadeh; Ahmad Poursadegh Zonouzi; Kazem Nejati-Koshki; Mohammad Shekari
Journal:  Med Oncol       Date:  2015-06-16       Impact factor: 3.064

2.  Prognostic relevance of ATM protein in uveal melanoma and its association with clinicopathological factors.

Authors:  Jayanti Jha; Mithalesh Kumar Singh; Lata Singh; Neelam Pushker; Mandeep Singh Bajaj; Seema Sen; Seema Kashyap
Journal:  Int J Clin Oncol       Date:  2019-08-03       Impact factor: 3.402

3.  Lack of association between cyclin D1 A870G (rs9344) polymorphism and esophageal squamous cell carcinoma risk: case-control study and meta-analysis.

Authors:  Weifeng Tang; Ping Yu; Yafeng Wang; Mingqiang Kang; Bin Sun; Jun Yin; Haiyong Gu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

4.  ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.

Authors:  S Rondeau; S Vacher; L De Koning; A Briaux; A Schnitzler; W Chemlali; C Callens; R Lidereau; I Bièche
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

5.  Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.

Authors:  Xiaolan Feng; Haocheng Li; Michelle Dean; Holly E Wilson; Elizabeth Kornaga; Emeka K Enwere; Patricia Tang; Alexander Paterson; Susan P Lees-Miller; Anthony M Magliocco; Gwyn Bebb
Journal:  Breast Cancer Res       Date:  2015-05-03       Impact factor: 6.466

Review 6.  Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

Authors:  Gwenola Manic; Florine Obrist; Antonella Sistigu; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-02-23

7.  Relationship Study of The Verified H uman Epidermal Growth Factor Receptor 2 Amplification with Other Tumor Markers and Clinicohistopathological Characteristics in Patients with Invasive Breast Cancer, Using Chromogenic In Situ Hybridization.

Authors:  Abdolazim Sarli; Hossein Mozdarani; Nasser Rakhshani; Sohail Mozdarani
Journal:  Cell J       Date:  2019-06-15       Impact factor: 2.479

Review 8.  Genetic and molecular biology of breast cancer among Iranian patients.

Authors:  Meysam Moghbeli
Journal:  J Transl Med       Date:  2019-07-08       Impact factor: 5.531

9.  Variation of ATM Gene Expression in Peripheral Blood Cells of Sporadic Breast Carcinomas in Iranian Patients.

Authors:  Mohsen Foroughizadeh; Hossein Mozdarani; Keyvan Majidzadeh-A; Ahmad Kaviani
Journal:  Avicenna J Med Biotechnol       Date:  2012-04

Review 10.  Multifunctional role of ATM/Tel1 kinase in genome stability: from the DNA damage response to telomere maintenance.

Authors:  Enea Gino Di Domenico; Elena Romano; Paola Del Porto; Fiorentina Ascenzioni
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.